# Annovis Bio, Inc.: overview ANVS · NYSE · CIK 1477845 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/anvs.md) · [Financials](/companies/anvs/financials.md) · [Filings](/companies/anvs/filings.md) · [Insiders](/companies/anvs/insiders.md) Latest reported revenue: [$0](/filings/0001104659-26-097228.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-097228). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0 d](/filings/0001558370-24-015074.md) | [0.0 d](/filings/0001558370-25-003482.md) | [0.0](/filings/0001558370-25-007584.md) | [0.0 d](/filings/0001558370-25-011233.md) | [0.0 d](/filings/0001104659-25-110393.md) | [0.0 d](/filings/0001104659-26-027751.md) | [0.0](/filings/0001104659-26-062626.md) | [0.0 d](/filings/0001104659-26-097228.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.97)](/filings/0001104659-25-110393.md) | not reported | [(0.32)](/filings/0001104659-26-062626.md) | [(0.32)](/filings/0001104659-26-097228.md) | [(0.37)](/filings/0001104659-25-110393.md) | not reported | [(0.63)](/filings/0001104659-26-062626.md) | [(0.40)](/filings/0001104659-26-097228.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001558370-22-002668.md) | [0.0](/filings/0001104659-23-040275.md) | [0.0](/filings/0001558370-24-004393.md) | [0.0](/filings/0001558370-25-003482.md) | [0.0](/filings/0001104659-26-027751.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.90)](/filings/0001104659-23-040275.md) | [(3.10)](/filings/0001558370-24-004393.md) | [(6.23)](/filings/0001558370-25-003482.md) | [(2.31)](/filings/0001104659-26-027751.md) | [(1.40)](/filings/0001104659-26-027751.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/anvs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Empery Asset Management, LP](/funds/1469336.md) | 2026-06-30 | $4.5m | 2,401,476 | | New +2,401,476 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.4m | 1,842,339 | | Added +654,840 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.1m | 1,647,322 | | Added +774,941 | | [TUDOR INVESTMENT CORP ET AL](/funds/923093.md) | 2026-06-30 | $2.5m | 1,357,134 | | New +1,357,134 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.9m | 1,002,200 | | Added +654,600 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.1m | 579,571 | | Reduced −48,088 | | [Caption Management, LLC](/funds/1706766.md) | 2026-06-30 | $883.3k | 474,900 | Call | New +474,900 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $531.8k | 285,900 | Call | Added +62,600 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $528.1k | 283,817 | | Added +36,304 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $464.7k | 249,856 | | Added +110,323 | ## Recent filings [All 308 filings](/companies/anvs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 23:49 ET | [8-K](/filings/0001104659-26-116995.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-116995 | | 2026-09-11 | 20:53 ET | [DEF 14A](/filings/0001104659-26-107113.md) | Proxy statement, period 2026-10-14 | 0001104659-26-107113 | | 2026-08-14 | 20:31 ET | [10-Q](/filings/0001104659-26-097228.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097228 | | 2026-08-14 | 20:05 ET | [8-K](/filings/0001104659-26-097091.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-097091 | | 2026-07-10 | 01:06 ET | [8-K](/filings/0001104659-26-082341.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-082341 | | 2026-06-17 | 20:50 ET | [8-K](/filings/0001104659-26-075198.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-075198 | | 2026-05-20 | 20:15 ET | [8-K](/filings/0001104659-26-064514.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-064514 | | 2026-05-15 | 20:30 ET | [10-Q](/filings/0001104659-26-062626.md) | Quarterly report, period 2026-03-31 | 0001104659-26-062626 | | 2026-05-15 | 20:00 ET | [8-K](/filings/0001104659-26-062451.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-062451 | | 2026-04-30 | 20:55 ET | [DEF 14A](/filings/0001104659-26-053096.md) | Proxy statement, period 2026-06-17 | 0001104659-26-053096 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-027751.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4db162ab-8768-4e39-b8f8-0afacdc9e379) ## About the filer - CIK: 1477845 - Tickers: ANVS - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.